Comparative Pharmacology
Head-to-head clinical analysis: ABREVA versus INCIVEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABREVA versus INCIVEK.
ABREVA vs INCIVEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Apply a thin layer to the affected area 5 times daily for 4 days.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
None Documented
None Documented
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Category C
Category C
Antiviral
Antiviral